"I reckon that if there was any hint on the current phase 3 trials not panning out they would not be aggressively pursuing global licensing deals, nor would Advanz Pharma have gone ahead with entering into a deal and parting with $10.8 million straight up"
Absolutely! Management knows it is efficacious from Stage 2a. That's why Nina so enthusiastically responded to the Stocks Down Under interviewer that champagne and popping corks will be in readiness for March 15.
They just need the Phase 3 interim read-out to demonstrate that the efficacy is also statistically significant.
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
58.0¢ |
Change
-0.015(2.52%) |
Mkt cap ! $346.8M | |||
| Open | High | Low | Value | Volume |
| 60.0¢ | 60.5¢ | 58.0¢ | $628.9K | 1.068M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 112279 | 58.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 58.5¢ | 39574 | 6 |
View Market Depth
| Last trade - 11.22am 27/06/2025 (20 minute delay) ? |
| DXB (ASX) Chart |